5-tert-butyl-thiophene-2-sulphonyl chloride | 179400-17-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-tert-butyl-thiophene-2-sulphonyl chloride
• 英文别名: 5-tert.-butyl-thiophene-2-sulfonyl chloride；5-Tert-butylthiophene-2-sulfonyl chloride
• CAS: 179400-17-0
• 化学式: C₈H₁₁ClO₂S₂
• mdl: MFCD19200289
• 分子量: 238.759
• InChiKey: JWHLHIKHBZVZNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  70.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-tert-butyl-thiophene-2-sulphonyl chloride 在 ammonium hydroxide 作用下， 以 氯仿 为溶剂， 反应 0.5h， 生成 5-tert-butyl-2-thiophenesulfonamide
  参考文献：
  名称：

  Sulfonylureas: a new class of cancer chemotherapeutic agents

  摘要：

  This study summarizes the antitumor properties of a number of sulofenur thiophene analogs against subcutaneously implanted 6C3HED lymphosarcoma with structural modification of the aryl moiety of the sulfonamide portion of the diarylsulfonylureas. The spectrum of activity of N-(p-chlorophenyl)-N'-[(5-methoxy-2-thienyl)sulfonyl]urea in the HXGC3, VRC5, CX-1, and LX-1 cell lines is also presented.

  DOI：

  10.1021/jm00094a013
• 作为产物：
  描述：

  2-溴-5-(1,1-二甲基乙基)-噻吩 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 N-氯代丁二酰亚胺 、 溶剂黄146 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 甲苯 为溶剂， 反应 1.0h， 生成 5-tert-butyl-thiophene-2-sulphonyl chloride
  参考文献：
  名称：

  [EN] SULFONANILIDE AND BENZYLSULFONYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
  [FR] DÉRIVÉS DE SULFONANILIDE ET BENZYLSULFONYLE, ET COMPOSITIONS ET PROCÉDÉS ASSOCIÉS

  摘要：

  这项发明提供了新型磺胺苯胺和苯基磺酰衍生物，以及其制备和使用的组合物和方法，可用于治疗与TRPML活性相关的各种疾病和紊乱，如溶酶体贮积症、肌肉营养不良、与年龄相关的常见神经退行性疾病、氧化应激或与活性氧（ROS）相关的疾病以及衰老。

  公开号：

  WO2022076383A1

文献信息

• Cannabinoid receptor ligands
  申请人：Schering Corporation

  公开号：US20040010013A1

  公开（公告）日：2004-01-15

  There are disclosed compounds of the formula I: 1 or a pharmaceutically acceptable salt of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.

  公开了以下式I的化合物： 1 或者该化合物的药用盐，具有抗炎和免疫调节活性。还公开了含有这些化合物的药物组合物。
• BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS
  申请人：SHANAGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

  公开号：US20160096811A1

  公开（公告）日：2016-04-07

  Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine D 3 receptor, 5-HT 1A receptor and 5-HT 2A receptor, but also can observably improve the symptoms of schizophrenia relevant to apomorphine model and MK-801 model mice, with oral absorption being good, safety being high and side-effect being less, and having developmental value as new anti-neurotic disease drugs. The present invention is the compounds having a structure of general formula (I), or geometric isomers, free alkalies, salts, hydrates or solvates thereof.

  本发明涉及苯并异噻唑化合物及其在制备抗精神分裂症药物中的应用。本发明的苯并异噻唑化合物不仅具有与多巴胺D3受体、5-HT1A受体和5-HT2A受体的强亲和力，而且可以明显改善与阿泼吗啡模型和MK-801模型小鼠相关的精神分裂症症状，口服吸收良好，安全性高，副作用少，并具有作为新型抗神经症药物的开发价值。本发明是具有通式（I）结构的化合物，或其几何异构体、自由碱、盐、水合物或溶剂化物。
• Sulphonamides
  申请人：Hoffmann-La Roche Inc.

  公开号：US05837708A1

  公开（公告）日：1998-11-17

  Compounds of the formula ##STR1## wherein the variables are hereinbelow defined. The compounds of formula I are inhibitors for endothelin receptors. They can be used for the treatment of disorders which are associated with endothelin activities, especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris.

  式子为##STR1##的化合物，其中变量如下所定义。公式I的化合物是内皮素受体抑制剂。它们可用于治疗与内皮素活动有关的疾病，特别是循环系统疾病，如高血压，缺血，血管痉挛和心绞痛。
• HETEROCYCLIC TRPML1 AGONISTS
  申请人：Libra Therapeutics, Inc.

  公开号：EP3821947A1

  公开（公告）日：2021-05-19

  The invention relates to a compound of formula (I) or a stereoisomer thereof, or a salt of any of the foregoing and to processes for its preparation. The compounds of formula (I) are useful in the treatment TRPML1- mediated disorders or diseases.

  该发明涉及公式(I)的化合物或其立体异构体，或任何上述化合物的盐，以及其制备的过程。公式(I)的化合物在治疗TRPML1介导的疾病或疾病中有用。
• Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
  申请人：Hoffmann-La Roche Inc.

  公开号：US05877193A1

  公开（公告）日：1999-03-02

  The invention is concerned with the use of sulfonamide derivatives of the general formula ##STR1## wherein R signifies lower-alkyl, phenyl, benzyl, naphthyl, pyridyl or thienyl, optionally substituted by one or more lower-alkyl, lower-alkoxy, lower-alkyl carbonyl-amino, halogen, cycloalkyl, nitro, amino, methylenedioxy, phenoxy or benzyloxy substituents, and the aromatic rings, can, in turn, be substituted by nitro, halogen or amino, R.sup.1 -R.sup.4 signify hydrogen, halogen, hydroxy, lower-alkyl, nitro, cyano, amino, lower-alkoxy, benzyloxy, trifluoromethyl or phenyl, optionally substituted by one or more lower-alkyl, trifluoromethyl, nitro, amino or hydroxy substituents, and wherein R.sup.1 and R.sup.2 or R.sup.2 and R.sup.3 together can form a benzene ring which optionally can be substituted by halogen, trifluoromethyl, nitro, lower-alkyl or lower alkoxy, and of their pharmaceutically acceptable salts as kynurenin-3-hydroxylase inhibitors in the control or prevention of neuro-degenerative disorders, neurological disorders resulting from an activation of the immune system, or psychiatric illnesses and, respectively, for the production of corresponding medicaments.

  本发明涉及磺酰胺衍生物的使用，其一般式为 ##STR1## 其中R表示低烷基、苯基、苄基、萘基、吡啶基或噻吩基，可选地被一个或多个低烷基、低烷氧基、低烷基羰基氨基、卤素、环烷基、硝基、氨基、亚甲二氧基、苯氧基或苄氧基基团取代，芳香环可以被硝基、卤素或氨基取代，R.sup.1 -R.sup.4表示氢、卤素、羟基、低烷基、硝基、氰基、氨基、低烷氧基、苄氧基、三氟甲基或苯基，可选地被一个或多个低烷基、三氟甲基、硝基、氨基或羟基基团取代，其中R.sup.1和R.sup.2或R.sup.2和R.sup.3可以共同形成一个苯环，该苯环可选地被卤素、三氟甲基、硝基、低烷基或低烷氧基取代，以及其药学上可接受的盐，作为酪氨酸-3-羟化酶抑制剂，用于控制或预防神经退行性疾病、由免疫系统激活引起的神经系统疾病或精神疾病，分别用于生产相应的药物。